Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
FDA Fast Track Designation for iSCIB1+
Regulatory Filings Classification · 85% confidence The document is a press release via the London Stock Exchange’s RNS service announcing FDA Fast Track designation and clinical trial updates for Scancell’s lead immunotherapy. It is not a financial report, earnings release, management change, or other specific category but rather a general corporate/regulatory announcement. Therefore it falls under Regulatory Filings (RNS).
2026-04-28 English
Scancell announces CFO transition
Board/Management Information Classification · 94% confidence The document is an RNS announcement titled “Scancell announces CFO transition,” describing the departure of the current CFO and the appointment of an interim CFO. This is clearly an announcement of changes in senior management. Under the provided taxonomy, this falls under Board/Management Information (MANG).
2026-04-02 English
Half-year Financial Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Results for the six months ended 31 October 2025' for Scancell Holdings plc. It contains detailed financial statements, including a 'Consolidated Statement of Comprehensive Loss', analysis of R&D expenditure, administrative expenses, and cash position. It also provides a comprehensive business update on clinical trials (iSCIB1+, Modi-1, GlyMab). As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2025
2026-01-29 English
FDA clearance of IND application for iSCIB1+
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service). It announces that Scancell Holdings plc has received FDA clearance for an Investigational New Drug (IND) application for a Phase 3 clinical trial. This is a corporate announcement regarding clinical trial progress and regulatory status, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like earnings releases, annual reports, or M&A activity.
2026-01-26 English
Notice of Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Scancell Holdings plc regarding the upcoming release of their interim financial results and an invitation to an investor presentation. It does not contain the actual financial report, but rather serves as a notification of the publication date and event details. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-01-22 English
Continued improvement in PFS with iSCIB1+
Regulatory Filings Classification · 98% confidence The document is an official RNS (Regulatory News Service) announcement from Scancell Holdings plc regarding updated clinical trial data (SCOPE Phase 2). It details progression-free survival results, regulatory discussions, and upcoming investor presentations. While it contains clinical data, it is an initial announcement of results rather than a full scientific report or a quarterly financial report. It fits the definition of a Regulatory Filing (RNS) as it is a standard corporate announcement distributed via the London Stock Exchange's RNS platform.
2025-12-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.